Compare Abbott Laboratories (ABT) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs MobilEye Global Inc — how do they compare? Abbott Laboratories trades at $95.62 (market cap $166.94B), while MobilEye Global Inc trades at $8.92 (market cap $8.00B). The key difference: Abbott Laboratories is far larger — about 20.9× MobilEye Global Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals.
| ABT | MBLY | |
|---|---|---|
Market Cap | $166.94B | $8.00B |
Sector | Health | Technology |
52-Week High | $136.62 | $18.64 |
52-Week Low | $82.57 | $6.56 |
Enterprise Value | $193.69B | $6.66B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Mobileye (MBLY) trades at $10.00, up 4.49% today, with a bullish technical signal from moving averages and strong analyst support. The stock shows negative profitability with a net income margin of -203.97% in 2026 but maintains solid revenue growth, reaching $2.0B. Recent news highlights its strategic shift to launch a vertically integrated U.S. robotaxi service in 2027, positioning it against competitors like Waymo and Tesla.
The outlook is cautiously optimistic due to the robotaxi initiative's potential, but high execution risks and persistent losses pose challenges. Analysts project a consensus price target of $10.36, with 57.69% recommending Buy. Investors should weigh the growth opportunity against the company's current unprofitability and competitive pressures in the autonomous vehicle sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
